Investment
Features
FeesSafety
Academy
More
Pluang+

Paragon Labs expands leadership with Apogee team to advance biotech assets and launches Velaris Therapeutics.

Company Fundamentals
13 Oct 2026
PRNewsWire
View Source
Bullish
Paragon Labs expands leadership with Apogee team to advance biotech assets and launches Velaris Therapeutics.

Paragon Labs has strengthened its leadership by integrating the former senior team of Apogee Therapeutics following Apogee's $10.9 billion acquisition by AbbVie. This expanded team will support the clinical development of Paragon-discovered assets and spearhead new company formations, starting with Velaris Therapeutics, which focuses on therapies for pulmonary hypertension and cardiopulmonary diseases. Velaris, the ninth company launched from Paragon's discoveries, was recently acquired by Alaunos Therapeutics, enhancing its portfolio in cardiopulmonary treatments. This move leverages Paragon's proven model of combining discovery with clinical and operational expertise to accelerate bringing novel biologics to patients.

Paragon Labs and Velaris Therapeutics are the subjects of this update. For readers following the health sector, here is Pluang's market snapshot as of Oct 13, 2026 16:51 WIB: Of 128 priced health-sector US stocks tradable on Pluang, 80 rose and 41 fell today. Alcon AG (ALC) was priced at USD 65.28 with a 1-day change of +1.45% and 100% buy order activity, Ginkgo Bioworks Holdings Inc (DNA) was at USD 11.62 with a -1.44% change and 65% buy order activity, and Abeona Therapeutics Inc (ABEO) was at USD 4.83 with a -1.43% change.

More News

Schrödinger stock dips 5% amid $55M Tectora co-founding and upcoming earnings forecast.

Schrödinger stock dips 5% amid $55M Tectora co-founding and upcoming earnings forecast.

Schrödinger's stock fell 5.02% to $25.91 despite co-founding Tectora, a new biopharma venture with $55 million funding targeting immune and inflammatory treatments. The company, known for its molecular modeling software, holds a market value of about...

Analyst Insights
Bullish
49 minutes ago
Johnson & Johnson beats Q3 earnings estimates, driven by strong pharmaceutical growth.

Johnson & Johnson beats Q3 earnings estimates, driven by strong pharmaceutical growth.

Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...

Company Fundamentals
Bullish
57 minutes ago
TSMC Q3 revenue beats forecasts as AI chip demand fuels strong growth.

TSMC Q3 revenue beats forecasts as AI chip demand fuels strong growth.

TSMC's preliminary Q3 2026 revenue reached approximately NT$1.49 trillion, about 50% higher year-over-year and above management guidance, driven by strong AI chip demand. The company holds a dominant 73% share of the global pure-play foundry market, ...

Company Fundamentals
Bullish
1 hour ago
Inc. and SurveyMonkey launch Growth Signals to capture insights from fast-growing businesses.

Inc. and SurveyMonkey launch Growth Signals to capture insights from fast-growing businesses.

Inc. and SurveyMonkey have launched Growth Signals, a new initiative to regularly poll entrepreneurs and business leaders of fast-growing companies. This program aims to capture their priorities, challenges, and growth outlook to inform Inc.'s editor...

Others
Neutral
1 hour ago
BNB Standard launches new website with real-time treasury dashboard to boost transparency and educate investors.

BNB Standard launches new website with real-time treasury dashboard to boost transparency and educate investors.

BNB Standard Corporation has launched a new corporate website featuring an expanded treasury dashboard that updates its Adjusted Net Asset Value and other key financial metrics intraday. This move aims to increase transparency and accountability in t...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App